BREAKING
Apollo Q4 2025 Earnings Rocket: Historic AUM Breakthrough 58 minutes ago Anavex Q1 2026 Earnings Rise: Breakthrough Drug Nears 3 hours ago Dynatrace Shares Rise After Q3 Fiscal 2026 Results Beat Guidance 5 hours ago Eli Lilly and Company (LLY) to acquire Orna Therapeutics 7 hours ago Earnings Summary: Becton, Dickinson and Company Q1 FY26 adjusted earnings decline 15% 8 hours ago Earnings Summary: Highlights of Apollo Global Management’s (APO) Q4 FY25 report 8 hours ago Earnings Summary: Loews Corporation reports sharp increase in Q4 FY25 profit 9 hours ago Plains All American weakens as NGL divestiture and cost cuts frame muted 2026 growth 11 hours ago Plains All American Streamlines, Targets Crude Growth Amid NGL Exit 11 hours ago Operational Efficiency Powers MGY to Historic Production and Dividend Lift 12 hours ago Apollo Q4 2025 Earnings Rocket: Historic AUM Breakthrough 58 minutes ago Anavex Q1 2026 Earnings Rise: Breakthrough Drug Nears 3 hours ago Dynatrace Shares Rise After Q3 Fiscal 2026 Results Beat Guidance 5 hours ago Eli Lilly and Company (LLY) to acquire Orna Therapeutics 7 hours ago Earnings Summary: Becton, Dickinson and Company Q1 FY26 adjusted earnings decline 15% 8 hours ago Earnings Summary: Highlights of Apollo Global Management’s (APO) Q4 FY25 report 8 hours ago Earnings Summary: Loews Corporation reports sharp increase in Q4 FY25 profit 9 hours ago Plains All American weakens as NGL divestiture and cost cuts frame muted 2026 growth 11 hours ago Plains All American Streamlines, Targets Crude Growth Amid NGL Exit 11 hours ago Operational Efficiency Powers MGY to Historic Production and Dividend Lift 12 hours ago
ADVERTISEMENT
AlphaGraphs

Key highlights from Abbott Laboratories (ABT) Q1 2024 earnings results

Abbott Laboratories (NYSE: ABT) reported its first quarter 2024 earnings results today. Total sales increased 2.2% year-over-year to $10 billion. Organic sales growth was 10.8%. Net earnings decreased 7% to $1.22 billion, or $0.70 per share, compared to last year. Adjusted EPS decreased 5% to $0.98. Abbott expects GAAP EPS of $3.25-3.40 and adjusted EPS of […]

$ABT April 17, 2024 1 min read

Abbott Laboratories (NYSE: ABT) reported its first quarter 2024 earnings results today.

Total sales increased 2.2% year-over-year to $10 billion. Organic sales growth was 10.8%.

Net earnings decreased 7% to $1.22 billion, or $0.70 per share, compared to last year. Adjusted EPS decreased 5% to $0.98.

Abbott expects GAAP EPS of $3.25-3.40 and adjusted EPS of $4.55-4.70 for full-year 2024. The company projects GAAP EPS of $0.69-0.73 and adjusted EPS of $1.08-1.12 for the second quarter of 2024.

Prior performance

Abbott Laboratories Q4 2023 earnings infographic
ADVERTISEMENT